On January 8, 2025, BrainAurora Medical Technology Limited (6681.HK, BrainAurora) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of HKD583 million. CBI is honored to participate in the due diligence work for this IPO Project.
BrainAurora is company offering digital therapeutics products for cognitive impairment in China. The company’s product pipeline covers both the assessment and intervention of a broad range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorders, and child development deficiencies, etc.
In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the group company, its directors, senior management, shareholders, suppliers and customers. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting related company search and reputation intelligence. The due diligence project globally covers 8 countries and regions, including China, Hong Kong, USA, Germany and the United Kingdom, etc.